BRPI0416376A - composições para a redução da colonização bacteriana e da invasão do snc e métodos de uso destes - Google Patents

composições para a redução da colonização bacteriana e da invasão do snc e métodos de uso destes

Info

Publication number
BRPI0416376A
BRPI0416376A BRPI0416376-1A BRPI0416376A BRPI0416376A BR PI0416376 A BRPI0416376 A BR PI0416376A BR PI0416376 A BRPI0416376 A BR PI0416376A BR PI0416376 A BRPI0416376 A BR PI0416376A
Authority
BR
Brazil
Prior art keywords
pneumococcal
methods
compositions
subject
invasion
Prior art date
Application number
BRPI0416376-1A
Other languages
English (en)
Inventor
Frederik W Van Ginkel
David E Briles
James M Watt
Original Assignee
Uab Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uab Research Foundation filed Critical Uab Research Foundation
Publication of BRPI0416376A publication Critical patent/BRPI0416376A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1275—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Streptococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01018—Exo-alpha-sialidase (3.2.1.18), i.e. trans-sialidase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"COMPOSIçõES PARA A REDUçãO DA COLONIZAçãO BACTERIANA E DA INVASãO SNC E MéTODOS DE USO DESTES". O presente pedido de patente de invenção se refere às composições designadas a reduzir ou prevenir as infecções bacterianas (por exemplo, as infecções pneumocócicas), colonização nasal, e a invasão do sistema nervoso central. é fornecida uma composição que compreende uma neuraminidase pneumocócica, fosfocolina, ácido teicóico pneumocócico, ácido lipoteicóico pneumocócico, ou uma parcela antigênica da neuraminidase, fosfocolina, ácido teicóico pneumocócico, ácido lipoteicóico pneumocócico. Opcionalmente, a composição pode compreender qualquer combinação de uma neurominidase pneumocócica, uma fosfocolina, um ácido teicóico pneumocócico, um ácido lipoteicóico pneumocócico ou uma parcela antigênica de qualquer um destes. Opcionalmente, os agentes são detoxificados. Além disso, são fornecidos métodos de preparo e de uso das composições divulgadas aqui. São fornecidos especificamente, métodos geradores de anticorpos em um sujeito que compreende a administração a um sujeito de um agente ou composição ensinada aqui. São fornecidos também métodos de redução ou prevenção da colonização nasal ou da infecção pneumocócica em um sujeito compreendendo a administração a um sujeito de uma composição ensinada aqui.
BRPI0416376-1A 2003-11-10 2004-11-10 composições para a redução da colonização bacteriana e da invasão do snc e métodos de uso destes BRPI0416376A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51879903P 2003-11-10 2003-11-10
PCT/US2004/037394 WO2005046721A2 (en) 2003-11-10 2004-11-10 Compositions for reducing bacterial carriage and cns invasion and methods of using same

Publications (1)

Publication Number Publication Date
BRPI0416376A true BRPI0416376A (pt) 2007-03-06

Family

ID=34590304

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0416376-1A BRPI0416376A (pt) 2003-11-10 2004-11-10 composições para a redução da colonização bacteriana e da invasão do snc e métodos de uso destes

Country Status (11)

Country Link
US (1) US9132179B2 (pt)
EP (1) EP1694359A2 (pt)
JP (2) JP2007512006A (pt)
KR (2) KR101289649B1 (pt)
CN (2) CN1909921B (pt)
AU (1) AU2004289295B2 (pt)
BR (1) BRPI0416376A (pt)
CA (1) CA2545325C (pt)
IL (1) IL175499A (pt)
WO (1) WO2005046721A2 (pt)
ZA (1) ZA200604754B (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7250494B2 (en) * 1998-06-15 2007-07-31 Biosynexus Incorporated Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of Gram positive bacteria
EP1981483A1 (en) 2006-01-24 2008-10-22 Nexbio, Inc. Technology for preparation of macromolecular microspheres
WO2008054475A2 (en) * 2006-03-13 2008-05-08 The Trustees Of Columbia University In The City Of New York Neuraminidase inhibitors and uses thereof
RU2445364C2 (ru) * 2006-04-17 2012-03-20 Шеринг-Плоу Лтд. Рекомбинантные аттенуированные микроорганизмы clostridium и вакцина
EP2081953A2 (en) * 2006-08-17 2009-07-29 The UAB Research Foundation Immunogenic pcpa polypeptides and uses thereof
AU2007353789B2 (en) * 2007-05-23 2014-05-22 The Uab Research Foundation Detoxified pneumococcal neuraminidase and uses thereof
WO2010057000A2 (en) * 2008-11-13 2010-05-20 The Trustees Of Columbia University In The City Of New York Neuraminidase inhibitors and uses thereof
US9040057B2 (en) * 2011-09-25 2015-05-26 Chang Gung Medical Foundation, Linkou Branch Method of diagnosing and preventing pneumococcal diseases using pneumococcal neuraminidases
EP2866792A4 (en) 2012-06-28 2016-08-17 Ansun Biopharma Inc MICROPARTICLE FORMULATIONS FOR DELIVERY TO LOWER AND CENTRAL RESPIRATORY PATHS AND METHOD OF PREPARING THEM
CN104056262B (zh) * 2013-03-20 2016-08-10 长庚医疗财团法人林口长庚纪念医院 具有对抗肺炎链球菌感染的蛋白疫苗组成物及检测样品中肺炎链球菌的方法
WO2017210476A1 (en) 2016-06-01 2017-12-07 Duke University Nonfouling biosensors
US11135301B2 (en) 2016-09-14 2021-10-05 Duke University Triblock polypeptide-based nanoparticles for the delivery of hydrophilic drugs
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
US11648200B2 (en) 2017-01-12 2023-05-16 Duke University Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly
US11680083B2 (en) 2017-06-30 2023-06-20 Duke University Order and disorder as a design principle for stimuli-responsive biopolymer networks
MX2020007024A (es) 2018-01-03 2020-10-28 Palleon Pharmaceuticals Inc Sialidasas humanas recombinantes, proteinas de fusion de sialidasa y metodos para usar las mismas.

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6027734A (en) * 1991-02-15 2000-02-22 Uab Research Foundation Mucosal administration of pneumococcal antigens
US6592876B1 (en) * 1993-04-20 2003-07-15 Uab Research Foundation Pneumococcal genes, portions thereof, expression products therefrom, and uses of such genes, portions and products
US5792457A (en) * 1991-05-03 1998-08-11 The Rockefeller University Antibody recognizing endothelial cell ligand for leukocyte CR3
US6312944B1 (en) * 1991-11-14 2001-11-06 The United States Of America As Represented By The Department Of Health And Human Services Pneumococcal fimbrial protein A
US5854416A (en) * 1991-11-14 1998-12-29 The United States Of America As Represented By The Department Of Health And Human Services Streptococcus pneumoniae 37-KDA surface adhesin a protein and nucleic acids coding therefor
WO1998018931A2 (en) * 1996-10-31 1998-05-07 Human Genome Sciences, Inc. Streptococcus pneumoniae polynucleotides and sequences
US6800744B1 (en) * 1997-07-02 2004-10-05 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
IS4518A (is) * 1997-07-09 1999-01-10 Lyfjathroun Hf, The Icelandic Bio Pharmaceutical Group Nýtt lyfjaform fyrir bóluefni
JP2002531055A (ja) * 1998-07-27 2002-09-24 マイクロビアル テクニクス リミティッド 肺炎連鎖球菌のタンパク質及び核酸分子
US6565856B1 (en) * 1998-12-08 2003-05-20 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
AT407958B (de) * 1999-02-11 2001-07-25 Immuno Ag Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation
GB0107658D0 (en) * 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
CA2444133A1 (en) * 2001-04-16 2002-10-24 Wyeth Holdings Corporation Novel streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof
US7202056B2 (en) * 2002-03-28 2007-04-10 Bristol-Myers Squibb Company Polynucleotides encoding a human cell surface protein with immunoglobulin folds, BGS-19
EP2426139B1 (en) * 2002-08-27 2014-10-01 Biokine Therapeutics Ltd. CXCR4 antagonist and use thereof
WO2004092209A2 (en) 2003-04-15 2004-10-28 Intercell Ag S. pneumoniae antigens
MXPA06014684A (es) * 2004-06-18 2007-02-12 Ambrx Inc Novedosos polipeptidos de enlace antigeno y sus usos.
US8404457B2 (en) * 2008-02-01 2013-03-26 Sanofi Pasteur Limited Assay for diagnosing Streptococcus pneumoniae

Also Published As

Publication number Publication date
IL175499A0 (en) 2006-09-05
ZA200604754B (en) 2007-10-31
KR20060126966A (ko) 2006-12-11
US9132179B2 (en) 2015-09-15
JP2007512006A (ja) 2007-05-17
AU2004289295B2 (en) 2010-08-12
CA2545325C (en) 2015-01-13
CN1909921A (zh) 2007-02-07
WO2005046721A2 (en) 2005-05-26
WO2005046721A3 (en) 2005-12-01
CN102861325A (zh) 2013-01-09
CA2545325A1 (en) 2005-05-26
EP1694359A2 (en) 2006-08-30
US20070286866A1 (en) 2007-12-13
IL175499A (en) 2017-03-30
JP2011160812A (ja) 2011-08-25
KR101289649B1 (ko) 2013-08-09
AU2004289295A1 (en) 2005-05-26
CN1909921B (zh) 2012-09-26
KR20110110825A (ko) 2011-10-07

Similar Documents

Publication Publication Date Title
BRPI0416376A (pt) composições para a redução da colonização bacteriana e da invasão do snc e métodos de uso destes
BR0307898A (pt) Formulações de droga antibiótica oftálmica contendo um composto de ciclodextrina e cloreto de cetil piridìnio
CY1118059T1 (el) Συνθεσεις αντιλοιμωδων βασει λιπιδιων για αγωγη πνευμονικων λοιμωξεων
BR0211613A (pt) Composições farmacêuticas contendo beta-lapachone ou derivados ou análogos seus, e processos de emprego das mesmas
BRPI0515520A (pt) composição imunogênica, vacina, métodos de preparar uma vacina e de prevenir ou tratar infecção estafilocócica, e, uso de composição imunogênica
BR0008590A (pt) Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto
BR0108173A (pt) Composições farmacêuticas de toxina de botulina
BRPI0113042B8 (pt) composto da fórmula ou um seu solvato fisiologicamente aceitável, uso do mesmo, composição farmacêutica, formulação farmacêutica, método para o tratamento de um indivíduo humano ou animal com uma condição inflamatória e/ou alérgica, e, processo para preparar um composto ou um seu solvato
DE69818707D1 (de) Chitosan und influenza-antigen(e) enthaltende impfstoff-zubereitungen zur verabreichung durch eine mukosa
BR0214343A (pt) Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1
BRPI0608877B8 (pt) composição imunogênica de rotavírus líquida, uso de um antígeno de rotavírus, um açúcar e um carboxilato, e, método para a preparação de uma composição de rotavírus líquida
BRPI0411505A (pt) uso de um composto, método para modular a resposta imune de um indivìduo, composição farmacêutica, vacina, complexo, e, kit para a captura de uma molécula biologicamente ativa
BRPI0410041A (pt) métodos para tratamento de dor de cabeça de sinusite
BRPI0414907A (pt) formulações farmacêuticas com liberação sustentada injetáveis, orais ou tópicas
BR9915988A (pt) Vacina para peptidase c5a estreptocócica
BR9914638A (pt) Composto, método para a preparação do mesmo, composição farmacêutica, uso de um composto, e, método para o tratamento de um distúrbio ou doença de um corpo de animal vivo
BRPI0412526A (pt) composto, uso de um composto, composição farmacêutica, formulação em aerossol farmacêutica, e, método para o tratamento de um paciente humano ou animal com uma condição anti-inflamatória e/ou alérgica
ATE418324T1 (de) Mucoadhäsive xyloglucan-haltige formulierung für medizinprodukte und pharmazeutische darreichungsformen
BRPI0416260A (pt) método para tratar, prevenir ou controlar uma doença ou distúrbio relacionada com amianto, e, composição farmacêutica
RS41104A (en) Sulphonamide derivatives, the preparation thereof and the application of same as medicaments
BR0309390A (pt) Composição farmacêutica
BRPI0406883A (pt) Composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto
FI964189A0 (fi) Immunogeeniset ryhmä A-streptokokkaaliset polysakkaridikoostumukset ja menetelmät
BRPI0408655A (pt) formulações compreendendo um agente ativo e cacau em pó e a sua utilização
BR0010983A (pt) Preparações para a aplicação de agentes antiinflamatórios

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL